Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Adrenergic Agonists: Therapeutic Uses

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reconsidering the interpretation of sperm DNA fragmentation testing in ART decision-making.

Human reproduction open·2026

Same author

Luteinizing hormone dynamics during progestin-primed ovarian stimulation do not predict follicular output in women with normo-ovarian reserve.

Frontiers in endocrinology·2026

Same author

How long is too long? The influence of the whole transfer procedure duration on pregnancy rates.

Journal of assisted reproduction and genetics·2026

Same author

SwimCount Harvester™ versus Density Gradient Centrifugation: A Pilot Study exploring Sperm DNA Fragmentation and Motile Sperm Recovery.

International braz j urol : official journal of the Brazilian Society of Urology·2026

Same author

High diagnostic accuracy and early prediction of ectopic pregnancy in patients with pregnancy of unknown location: a multicenter cohort study.

AJOG global reports·2026

Same author

Sperm DNA fragmentation: how to test, when to test, and what to do with abnormal results-a pragmatic mini-review for clinical practice.

Human reproduction (Oxford, England)·2026

Search research articles

Related Experiment Video

Updated: May 15, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

GnRH agonist triggering: recent developments.

Shahar Kol¹, Peter Humaidan

¹Department of Obstetrics and Gynecology, The IVF Unit, Rambam Medical Center, Haifa, Israel. skol@rambam.health.gov.il

Reproductive Biomedicine Online

|January 23, 2013

Summary

This summary is machine-generated.

Gonadotrophin-releasing hormone agonist (GnRHa) can replace human chorionic gonadotrophin (HCG) for final oocyte maturation. GnRHa trigger offers advantages like preventing ovarian hyperstimulation syndrome and individualizing luteal support.

More Related Videos

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

Triggering Reactive Gliosis In Vivo by a Forebrain Stab Injury

Triggering Reactive Gliosis In Vivo by a Forebrain Stab Injury

Published on: June 29, 2015

Related Experiment Videos

Last Updated: May 15, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

Triggering Reactive Gliosis In Vivo by a Forebrain Stab Injury

Triggering Reactive Gliosis In Vivo by a Forebrain Stab Injury

Published on: June 29, 2015

Area of Science:

Reproductive Endocrinology
Infertility Treatment

Background:

Human chorionic gonadotrophin (HCG) has been the standard trigger for final oocyte maturation.
Concerns exist regarding HCG's association with ovarian hyperstimulation syndrome (OHSS).

Purpose of the Study:

To evaluate the efficacy and benefits of using gonadotrophin-releasing hormone agonist (GnRHa) as an alternative trigger for oocyte maturation.
To challenge the conventional use of HCG triggering in assisted reproductive technologies.

Main Methods:

Review of recent developments and clinical data comparing GnRHa and HCG triggers.
Analysis of outcomes related to OHSS prevention, hormonal surges (LH and FSH), and luteal phase support.

Main Results:

GnRHa trigger significantly reduces the risk of OHSS.
GnRHa trigger elicits both LH and FSH surges, potentially enhancing follicular development.
Allows for individualized luteal-phase supplementation based on patient response.

Conclusions:

GnRHa trigger represents a safer and more adaptable alternative to HCG for final oocyte maturation.
Transitioning to GnRHa triggering is recommended for improved patient safety and personalized care in fertility treatments.